Alarming Rise in Breast and Cervical Cancers in Low- and Middle-Income Countries: Breaking Down Screening Barriers

By HEOR Staff Writer

July 5, 2023

Breast and cervical cancers are on the rise in low- and middle-income countries, with lower cure rates due to late diagnosis. Screening programs in these countries are not comprehensive, hindering early detection. 

By analysing studies published between 2016 and 2021, articles from low- and middle-income countries and using the 5A framework (approachability, acceptability, availability, affordability, and appropriateness), screening barriers were classified. 

Findings highlighted the lack of awareness, high screening costs, and distance to screening centers as major obstacles. Embarrassment, fear, and cultural factors also contribute to low screening rates. 

To combat these challenges, policymakers and governments must take action to enhance public confidence in healthcare systems. Evidence-based strategies are needed to educate women about cancer causes and risk factors, promoting increased adherence to screening. Together, we can make a difference in the fight against breast and cervical cancers worldwide.

Reference url

Recent Posts

Transforming Health: The Role of the South African Medical Research Council

By João L. Carapinha

May 4, 2026

South African Medical Research is driving meaningful progress in addressing the region’s most pressing health challenges. What are the priorities of the South African Medical Research Council for shaping the future of health? In a recent interview, President and CEO Ntobeko Ntusi explains how the...
Portugal Medicines Reserve: Strengthening Health System Resilience
The Portuguese Government has approved the establishment of a national and regional strategic reserve of medicines and medical devices under the Portugal Transformation, Recovery and Resilience (PTRR) plan, involving an investment of 70 million euros. This measure, announced by Prime Minister Luí...
Merck Q1 2026 Performance: Growth and Innovations in Oncology and Cardiometabolic Care

By HEOR Staff Writer

April 30, 2026

Merck’s first-quarter 2026 results have been published and highlight key growth drivers, regulatory achievements, and strategic moves that reinforce the company’s diversified portfolio. Oncology Dominance Fueled by KEYTRUDA Expansion Merck Q1 2026 performance was prima...